Revvity, Inc. (NYSE: RVTY) — Business Overview

Source filing: Form 10-K for fiscal year ended December 29, 2024, filed with the SEC (CIK 0000031791), available at: https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/revv-20241229.htm. Supplementary figures from Revvity's Q4/FY2024 earnings release (BusinessWire, January 31, 2025).

Executive Summary

Revvity, Inc. (formerly PerkinElmer, Inc., renamed in 2023 following the divestiture of its legacy Applied, Food, and Enterprise Services businesses to New Mountain Capital) is a Waltham, Massachusetts-headquartered health science company operating across two segments: Life Sciences and Diagnostics. The company generated $2,755 million in revenue for fiscal 2024 (roughly flat versus $2,751 million in fiscal 2023), with GAAP operating income of $347 million (12.6% margin) and an adjusted operating margin of 28.3%. Revvity sells reagents, instruments, software, and diagnostic testing technologies to pharmaceutical and biotech companies, contract research organizations, academic and government institutions, and hospitals and clinical laboratories in more than 160 countries, with approximately 11,000 employees, roughly 80% of whom are based outside the United States. The post-rebrand portfolio is narrower and higher-margin than the old PerkinElmer, concentrated on differentiated reagent chemistries (BioLegend, HTRF, AlphaLISA, Dharmacon), high-content imaging and screening instruments, software (Signals), and diagnostics franchises in reproductive health, immunodiagnostics, and applied genomics (including EUROIMMUN and NTD/newborn screening). The business competes against far larger, more diversified life-science tool and diagnostics companies — Thermo Fisher Scientific, Danaher, Agilent Technologies, and Bio-Rad Laboratories — occupying a position as a focused, reagent- and assay-oriented specialist rather than a broad-platform conglomerate. Strategic strengths include recurring consumables revenue, leading niche franchises in prenatal/newborn screening and autoimmune diagnostics, and a leaner cost structure post-divestiture; key risks include customer concentration in pharma/biotech R&D spending cycles (which weakened in 2023–2024), exposure to NIH/academic and Chinese government funding, substantial goodwill and intangible assets ($9.1 billion net as of fiscal year-end 2024) vulnerable to impairment, and ongoing integration risk from its active M&A and licensing strategy (e.g., BioLegend).

1. Core Business Model

Revvity operates a "razor-and-razorblade" model: it sells capital instruments, software, and diagnostic platforms (the "razor") that create a durable installed base, which in turn drives recurring, higher-margin sales of reagents, consumables, assay kits, and service/support contracts (the "razorblades"). Revenue also flows from licensing of proprietary technologies (e.g., gene-editing and cell-line IP) to pharma and biotech partners.

        DISCOVERY ─────────► DEVELOPMENT ─────────► DIAGNOSIS ─────────► CURE/MONITORING
   (Life Sciences segment)                                        (Diagnostics segment)

   ┌───────────────┐      ┌───────────────┐      ┌───────────────┐      ┌───────────────┐
   │  Reagents &   │─────►│  Instruments  │─────►│  Software &   │─────►│  Recurring     │
   │  Assay Kits   │      │  (imaging,    │      │  Licensing/    │      │  Reagent &     │
   │ (BioLegend,   │      │  screening,   │      │  IP            │      │  Service       │
   │  HTRF, Alpha- │      │  liquid       │      │ (Signals,      │      │  Revenue       │
   │  LISA,        │      │  handling)    │      │  ChemDraw,     │      │  (installed-   │
   │  Dharmacon)   │      │               │      │  Pin-point)    │      │  base pull-    │
   └───────────────┘      └───────────────┘      └───────────────┘      │  through)      │
                                                                         └───────────────┘
   ┌────────────────────────────── Diagnostics flywheel ───────────────────────────────┐
   │  Prenatal/Newborn Screening → Immunodiagnostics (autoimmune, CSF) → Applied Genomics │
   │  (sample prep, NGS library kits) → Omics testing labs → repeat testing volume      │
   └──────────────────────────────────────────────────────────────────────────────────┘

Roughly 80% of Life Sciences revenue and the majority of Diagnostics revenue is recurring in nature (reagents, kits, consumables, and service), which smooths cyclicality in the underlying instrument capex cycle.

2. Business Segments

Life Sciences — Serves pharmaceutical and biotech companies, contract research organizations (CROs), and academic/government institutions across cell, gene, and protein research workflows. FY2024 revenue was $1,254 million (Q4 2024: $336 million). Key offerings:

• Reagents: BioLegend antibodies and immunoassays, HTRF and AlphaLISA assay technologies, Dharmacon gene-modulation reagents (siRNA/RNAi).
• Instruments: Opera Phenix Plus and Operetta CLS high-content screening systems, EnVision multimode plate readers, IVIS in vivo imaging systems.
• Software: Signals ChemDraw and Signals Notebook informatics platforms.
• Technology & licensing: Pin-point base-editing technology, CHOSOURCE cell lines, and gene-delivery services licensed to biopharma partners.

Diagnostics — Serves hospitals, medical/reference laboratories, clinicians, and research professionals, organized around reproductive health, immunodiagnostics, emerging-market diagnostics, and applied genomics. FY2024 revenue was $1,502 million (Q4 2024: $393 million), making Diagnostics the larger of the two segments. Key offerings:

• Reproductive health: DELFIA Xpress prenatal screening, newborn screening kits, Vanadis non-invasive prenatal testing (NIPT), and Revvity Omics genetic testing laboratories.
• Immunodiagnostics: EUROIMMUN autoimmune disease testing, T-SPOT.TB tuberculosis testing, and Alzheimer's CSF biomarker assays.
• Applied genomics: Automated sample preparation and liquid handling (Omni Bead Ruptor, JANUS, chemagic platforms), plus next-generation sequencing (NGS) library preparation kits.

3. Product Portfolio

4. Competitive Landscape

Revvity competes against far larger, broadly diversified life-science tools and diagnostics conglomerates as well as specialized reagent and diagnostics companies. Management expects continued industry consolidation among large players. Competitive factors cited in the 10-K include service level, price, innovation, quality, and reliability.

                    BROAD PLATFORM BREADTH
                            ▲
                            │
                 Thermo Fisher ●  (~$42B revenue; instruments,
                            │     reagents, CRO, pharma services)
                            │
              Danaher ●     │
         (~$23B; life sci + │
          diagnostics + water)
                            │
    Agilent ●               │                 ● Revvity
 (~$6.3B; analytical &      │              (~$2.8B; focused
  life science instruments) │               reagents/assays +
                            │               reproductive health &
                            │               immunodiagnostics niches)
                            │        ● Bio-Rad
                            │     (~$2.5B; life science &
                            │      clinical diagnostics reagents)
                            │
                            └──────────────────────────────────►
                       LOW                              HIGH
                    NICHE/REAGENT FOCUS           DIAGNOSTICS/CLINICAL DEPTH

Revvity sits as the smallest of the large-cap tools peer set by revenue, but is differentiated by depth in two specific niches — prenatal/newborn screening (DELFIA, Vanadis) and autoimmune diagnostics (EUROIMMUN) — where it holds leading or near-leading share, alongside a high-value reagent and antibody franchise (BioLegend) acquired to bolster the Life Sciences segment's recurring revenue mix. Thermo Fisher and Danaher compete on scale and breadth (including pharma services and bioprocessing); Agilent and Bio-Rad compete more directly on analytical instruments and reagents at a similar sub-segment level.

5. Strategic Strengths & Risks

Strengths

• High recurring-revenue mix from reagents, consumables, and diagnostic test kits tied to an installed instrument and testing base.
• Leading or top-tier niche positions in prenatal/newborn screening and autoimmune/infectious disease immunodiagnostics (EUROIMMUN, DELFIA, Vanadis).
• Leaner, higher-margin portfolio following the 2023 divestiture of the legacy Applied, Food, and Enterprise Services businesses, which simplified the company into two focused, higher-growth segments.
• Global commercial footprint (160+ countries, ~80% of employees outside the U.S.) providing geographic diversification and emerging-market diagnostics exposure.
• Active technology licensing (Pin-point base editing, CHOSOURCE) generating partner revenue beyond direct product sales.

Risks

• Revenue is sensitive to pharmaceutical/biotech R&D spending cycles and academic/government research funding, both of which softened in 2023–2024 and remain exposed to policy changes (including NIH funding and China-related budget/stimulus dynamics).
• $9.1 billion of net intangible assets (including goodwill from BioLegend and other acquisitions) creates material impairment risk if end-market demand or acquired-business performance weakens.
• Substantial debt load and associated covenants constrain financial flexibility and create interest-rate/refinancing exposure.
• Supply chain dependence on limited or single-source suppliers for certain critical components, plus exposure to tariffs and trade-policy shifts given the global manufacturing and sales footprint.
• Heavy regulatory exposure (FDA and international diagnostics/device regulation, healthcare fraud and anti-corruption laws, data privacy) with associated recall, enforcement, and compliance cost risk.
• Integration risk from an active M&A and in-licensing strategy; failure to renew key licenses or successfully integrate acquisitions could impair returns.
• Cybersecurity and IT-system risk given reliance on digital platforms (e.g., Signals software, lab information systems) across a global operating footprint.

6. Financial Overview

All figures as reported in Revvity's FY2024 Form 10-K and Q4/FY2024 earnings release (fiscal years ended December 29, 2024 and December 31, 2023).

Note: Prior-year (FY2023) segment-level and margin detail was not present in the 10-K excerpt reviewed and is omitted rather than estimated.

7. Summary Conclusion

Revvity is a mid-cap, focused health science company that has deliberately traded the scale of its former PerkinElmer conglomerate structure for a tighter, higher-margin portfolio built around differentiated reagents, niche diagnostics franchises, and recurring consumables revenue. Against much larger diversified peers — Thermo Fisher, Danaher, Agilent, and Bio-Rad — Revvity cannot compete on breadth or balance-sheet scale, but it has carved out genuine leadership in specific, defensible niches: prenatal/newborn screening and autoimmune immunodiagnostics, complemented by a high-quality antibody and assay-reagent franchise in Life Sciences. The business generated roughly $2.76 billion in revenue in fiscal 2024 with a 28.3% adjusted operating margin, reflecting the benefits of the post-divestiture portfolio simplification, though GAAP margins remain compressed by amortization of the substantial intangible asset base built through M&A. The principal swing factors for investors to monitor are the pace of recovery in pharma/biotech and academic R&D spending, the durability of diagnostics testing volumes, and management's ability to protect returns on its large intangible-asset and goodwill base while continuing to pursue bolt-on licensing and acquisition opportunities.